Back |
home / stock / imnm / imnm message board
Subject | By | Source | When |
---|---|---|---|
The dilution is going to kill this run. | Pedro2004 | investorshub | 07/20/2021 2:38:33 PM |
Looks like the company is dumping shares on | Pedro2004 | investorshub | 07/20/2021 2:35:44 PM |
I don't think$ PFE and$ MRNA can claim | Major_Bankz | investorshub | 07/20/2021 2:32:34 PM |
Delta is a BIG problem, $IMNM may catch | Major_Bankz | investorshub | 07/20/2021 2:22:24 PM |
Immunome was awarded a $17.6 million technology award | Major_Bankz | investorshub | 07/20/2021 2:02:01 PM |
IMNM $21 Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the | Major_Bankz | investorshub | 07/20/2021 1:55:04 PM |
News, Short Squeeze, Breakout and More Instantly...
Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Tsai, PhD, as Chief Technical Officer. Dr. Tsai has nearly three decades of experience in product development, proces...
2024-05-21 22:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of antibodies and related assets from Atreca, Inc. Under the terms of the agreement, Immunome paid Atreca $5.5 mi...